Polymyxins B and E1 and gramicidin S are bacterium-derived cationic antimicrobial
peptides. The polymyxins were more potent than gramicidin S against Pseudomonas …

The in-vitro activity of cecropin P1, indolicidin, magainin II, nisin and ranalexin alone and in
combination with nine clinically used antimicrobial agents was investigated against a control …

Polymyxin B nonapeptide (PMBN), a cationic cyclic peptide derived by enzymatic
processing from the naturally occurring peptide polymyxin B, is able to increase the …

Multidrug-resistant Pseudomonas aeruginosa is a major cause of severe hospital-acquired
infections. Currently, polymyxin B (PMB) is a last-resort antibiotic for the treatment of …

Polymyxin B nonapeptide (PMBN), a cationic cyclic peptide derived from the antibacterial
peptide polymyxin B, is capable of specifically increasing the permeability of the outer …

The two‐component regulatory system PhoP‐PhoQ of Pseudomonas aeruginosa regulates
resistance to cationic antimicrobial peptides, polymyxin B and aminoglycosides in response …

Novel approaches for the treatment of multidrug-resistant Gram-negative bacterial infections
are urgently required. One approach is to potentiate the efficacy of existing antibiotics whose …

A synthetic peptide, KFFKFFKFFK [corrected], consisting of cationic lysine residues and
hydrophobic phenylalanine residues was found to sensitize gram-negative bacteria to …

Polymyxin B and colistin (polymyxin E) are bactericidal pentacationic lipopeptides that act
specifically on Gram-negative bacteria, first by disrupting their outermost permeability …

Polymyxins are cationic antimicrobial peptides used as the last-line therapy to treat
multidrug-resistant Gram-negative bacterial infections. The bactericidal activity of polymyxins …